Brii Biosciences Limited (HKG:2137)

Brii Biosciences Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	502.98	606.84	1,003	489.65	1,191	2,855
Short-Term Investments	1,266	1,333	1,317	2,171	1,807	499.65
Cash & Short-Term Investments	1,769	1,940	2,320	2,661	2,997	3,355
Cash Growth	-14.72%	-16.41%	-12.79%	-11.23%	-10.65%	217.99%
Other Receivables	-	-	-	71.09	57.72	51.52
Receivables	-	-	-	71.09	57.72	51.52
Other Current Assets	15.32	23.07	93.81	51.03	21.79	7.68
Total Current Assets	1,785	1,963	2,414	2,783	3,077	3,414
Property, Plant & Equipment	19.3	14.17	14.3	5.61	19.52	33.44
Long-Term Investments	30.57	7.43	9.2	142.44	146.03	152.03
Other Intangible Assets	288.78	298.02	179.71	267.42	146.89	9.51
Other Long-Term Assets	76.38	77.38	89.3	-	2.51	2.79
Total Assets	2,200	2,360	2,707	3,198	3,392	3,612

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	27.62	24.74	52.94	68.63	150.87	205.83
Current Portion of Leases	3.98	5.04	4.9	3.16	9.5	8.97
Current Income Taxes Payable	0.87	1.21	1.19	2.01	1.86	1.65
Current Unearned Revenue	-	-	16.94	50.63	54.68	52.88
Other Current Liabilities	1.69	1.33	1.46	1.44	12.2	11.38
Total Current Liabilities	34.17	32.31	77.42	125.87	229.11	280.71
Long-Term Debt	-	-	17.97	-	-	-
Long-Term Leases	2.2	3.89	5.15	-	3.16	12.65
Long-Term Unearned Revenue	-	-	-	-	2.08	7.08
Total Liabilities	36.36	36.2	100.55	125.87	234.35	300.44

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	-	9,402	9,390	9,377	9,352	9,317
Retained Earnings	-	-7,473	-7,205	-6,697	-6,522	-6,038
Treasury Stock	-	-16.9	-0	-0.07	-	-
Comprehensive Income & Other	2,216	463.45	472.27	439.28	364.69	63.71
Total Common Equity	2,216	2,376	2,657	3,119	3,195	3,343
Minority Interest	-52.74	-52.32	-50.88	-46.66	-37.12	-31.65
Shareholders' Equity	2,163	2,323	2,606	3,072	3,157	3,311
Total Liabilities & Equity	2,200	2,360	2,707	3,198	3,392	3,612

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	6.18	8.93	28.02	3.16	12.66	21.62
Net Cash (Debt)	1,763	1,931	2,292	2,658	2,985	3,333
Net Cash Growth	-14.71%	-15.78%	-13.74%	-10.96%	-10.45%	-
Net Cash Per Share	2.42	2.67	3.14	3.65	4.13	7.59
Filing Date Shares Outstanding	734.4	721.18	731.31	729.39	727.2	720.29
Total Common Shares Outstanding	734.4	721.18	731.31	729.39	727.2	720.29
Working Capital	1,750	1,930	2,337	2,657	2,848	3,133
Book Value Per Share	3.02	3.29	3.63	4.28	4.39	4.64
Tangible Book Value	1,927	2,078	2,477	2,852	3,048	3,333
Tangible Book Value Per Share	2.62	2.88	3.39	3.91	4.19	4.63
Machinery	-	3.31	3.71	0.34	0.34	0.34
Construction In Progress	-	1.53	-	-	-	-
Leasehold Improvements	-	24.84	24.84	24.84	24.84	24.84

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 26, 2026

Data Sources Report a data error